Intelligence Feed event · Equity · 2026-10-01

    Merck Faces 12.8% EPS Contraction Forecast Ahead of October 29 Print

    Question

    Merck Faces 12.8% EPS Contraction Forecast Ahead of October 29 Print

    Direct answer

    Shares of Merck (MRK) fell 2.66% to $145.31 on September 30, underperforming broader equity benchmarks. The pharmaceutical company is scheduled to report third-quarter 2026 results on October 29, with analysts anticipating $17.52 billion in revenue (+1.39% YoY) and EPS of $2.25 (-12.79% YoY).

    Original publisher
    Market Ontology
    Evidence through
    2026-10-01
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Merck Faces 12.8% EPS Contraction Forecast Ahead of October 29 Print”, revision 1, evidence through 2026-10-01. https://marketontology.com/market-events/2026-10-01/merck-faces-12-8-eps-contraction-forecast-ahead-of-october-29-print-1f0ff9

    EQUITY
    Merck Faces 12.8% EPS Contraction Forecast Ahead of October 29 Print
    Shares of Merck (MRK) fell 2.66% to $145.31 on September 30, underperforming broader equity benchmarks. The pharmaceutical company is scheduled to report third-quarter 2026 results on October 29, with analysts anticipating $17.52 billion in revenue (+1.39% YoY) and EPS of $2.25 (-12.79% YoY).
    MRKXLV
    Impact
    59
    OCT 1
    SIG
    85%
    MRKXLV
    Merck Faces 12.8% EPS Contraction Forecast Ahead of October 29 Print
    Shares of Merck (MRK) fell 2.66% to $145.31 on September 30, underperforming broader equity benchmarks. The pharmaceutical company is scheduled to report third-quarter 2026 results on October 29, with analysts anticipating $17.52 billion in revenue (+1.39% YoY) and EPS of $2.25 (-12.79% YoY).
    → A projected 12.79% YoY decline in Q3 EPS to $2.25 pressures MRK trading multiples heading into the October 29 reporting date.
    Impact
    Shares of Merck (MRK) fell 2.66% to $145.31 on September 30, underperforming broader equity benchmarks. The pharmaceutical company is scheduled to report third-quarter 2026 results on October 29, with analysts anticipating $17.52 billion in revenue (+1.39% YoY) and EPS of $2.25 (-12.79% YoY).
    Affected
    MRKXLV
    Transmission
    A projected 12.79% YoY decline in Q3 EPS to $2.25 pressures MRK trading multiples heading into the October 29 reporting date.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    MRKquarterly earnings multiple compression on projected 12.79% EPS dropMixed1-4wQ3 2026 EPS consensus is $2.25 versus prior-year period.
    XLVlarge-cap biopharma revenue weightingMixed1-4wMRK is a core holding in US healthcare and pharmaceutical sector benchmarks.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    XLVMixed166.20 2026-10-01-0.01%+1.18%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month